Clinical Research Directory

Inclusion Criteria: * Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma * FIGO stage IB3, IIA2, IIB-IVA patients in 2018 * Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment * Aged 18-75 years * PS score 0-1 * Serum hemoglobin \>=100\*10\^9/L, blood platelet \>= 100000/μL, absolute count of neutrophils\>=1500/μL; 7.Serum creatinine \<=1.5 UNL or creatinine clearance \>= 60 ml/min; 8.Serum bilirubin \<=1.5 UNL, AST (SGOT) and ALT (SGPT)\<= 1.5 UNL * Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \> 6 months. Exclusion Criteria: * Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment * Patients who have received neoadjuvant chemotherapy and surgery * Patients with cognitive impairment * Patients with any distant metastases * Patients with any other malignancy within 5 years * Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception * Severe bone marrow dysfunction * Patients with bleeding tendency * Drug abusers or alcohol addicts * Those who are known to have a third or fourth degree allergic reaction to any treatment in the study